UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or Organi ...

Scientific Solutions Without Compromise June 10, 2021 Conference Call and Webcast E 0 M Q:TY A D S A M / N O C.C EIN M TY Safe Harbor Statement TY In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their cli ...

Tyme Technologies, Inc. (TYME) Q1 2021 Earnings Conference Call June 10, 2021 5:00 PM ET Company Participants Richie Cunningham - CEO Jan Tornout - Acting Chief Medical Officer Frank Porfido - CFO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Hello, and welcome to the Tyme Technologies, Inc. Fiscal Year 2021 Financial Results and Business Update Conference Call. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Following the p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or Organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

| --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | An Expression Makes a World of Difference | | | | | March 2021 | | | | Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inclu ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Naomi Aoki - Vice President, Corporate Communications and Investor Relations Nancy Simonian - Our Chief Executive Officer David Roth - Chief Medical Officer Joe Ferra - Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen Ted Tenthoff - Piper Sandler Jason Butler - JMP Securities Mark Breidenbach - Oppenheimer Zegbeh Jallah - ROTH Capital Matthew Cross - Alliance Globa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or other jurisdic ...

| --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | An Expression Makes a World of Difference | | | | | January 2021 | | | | Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inc ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Naomi Aoki – Vice President of Corporate Communications and Investor Relations Nancy Simonian – Chief Executive Officer David Roth – Chief Medical Officer Joe Ferra – Chief Financial Officer Conference Call Participants Kenneth Atkins – Cowen Ted Tenthoff – Piper Sandler Roy Buchanan – JMP Securities Zegbeh Jallah – ROTH Capital Partners Matt Biegler – Oppenheimer Matthew Cross – Allia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or O ...